{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:06:40Z","timestamp":1790474800007,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002543","name":"Pusan National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1A2B4009511"],"award-info":[{"award-number":["NRF-2017R1A2B4009511"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.omtm.2021.04.015","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:13:51Z","timestamp":1619838831000},"page":"702-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation"],"prefix":"10.1016","volume":"21","author":[{"given":"Kyowon","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeil","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2021.04.015_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/mus.25367","article-title":"Progress and challenges in diagnosis of dysferlinopathy","volume":"54","author":"Fanin","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2021.04.015_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1172-8-26","article-title":"Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial","volume":"8","author":"Walter","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2021.04.015_bib3","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/brain\/awp236","article-title":"Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population","volume":"132","author":"Norwood","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2021.04.015_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/brain\/123.6.1229","article-title":"Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features","volume":"123","author":"Argov","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2021.04.015_bib5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.nmd.2011.12.007","article-title":"Two common mutations (p.Gln832X and c.663+1G>C) account for about a third of the DYSF mutations in Korean patients with dysferlinopathy","volume":"22","author":"Park","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2021.04.015_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.nmd.2015.03.006","article-title":"Targeted next-generation sequencing for the genetic diagnosis of dysferlinopathy","volume":"25","author":"Shin","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2021.04.015_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2021.04.015_bib8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2021.04.015_bib9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/bioinformatics\/btv195","article-title":"PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels","volume":"31","author":"Choi","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtm.2021.04.015_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtm.2021.04.015_bib11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2021.04.015_bib12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"10.1016\/j.omtm.2021.04.015_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41598-017-01093-9","article-title":"Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes","volume":"7","author":"Bolze","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2021.04.015_bib14","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.04.015_bib15","doi-asserted-by":"crossref","first-page":"e1001593","DOI":"10.1371\/journal.pbio.1001593","article-title":"A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays","volume":"11","author":"McElroy","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omtm.2021.04.015_bib16","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.04.015_bib17","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/archneur.62.8.1256","article-title":"Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population","volume":"62","author":"Vilchez","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.omtm.2021.04.015_bib18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/japplphysiol.01366.2009","article-title":"Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression","volume":"109","author":"Wang","year":"2010","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.omtm.2021.04.015_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2199-2-3","article-title":"UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals","volume":"2","author":"Cassan","year":"2001","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.omtm.2021.04.015_bib20","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.04.015_bib21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1261\/rna.054452.115","article-title":"Rules of UGA-N decoding by near-cognate tRNAs and analysis of readthrough on short uORFs in yeast","volume":"22","author":"Beznoskov\u00e1","year":"2016","journal-title":"RNA"},{"key":"10.1016\/j.omtm.2021.04.015_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J.\u00a0Basic Clin. Pharm."},{"key":"10.1016\/j.omtm.2021.04.015_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2021.04.015_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev-med-120611-144851","article-title":"Ataluren as an agent for therapeutic nonsense suppression","volume":"64","author":"Peltz","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.omtm.2021.04.015_bib25","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/hmg\/ddh212","article-title":"Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency","volume":"13","author":"Ho","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.04.015_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1083\/jcb.139.2.375","article-title":"Animal models for muscular dystrophy show different patterns of sarcolemmal disruption","volume":"139","author":"Straub","year":"1997","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtm.2021.04.015_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2044-5040-1-35","article-title":"Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice","volume":"1","author":"Han","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtm.2021.04.015_bib28","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.04.015_bib29","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.ymthe.2018.07.021","article-title":"Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit","volume":"26","author":"Sreetama","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.04.015_bib30","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1172\/JCI91445","article-title":"Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy","volume":"127","author":"Quattrocelli","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2021.04.015_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","article-title":"Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy","volume":"13","author":"Lee","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2021.04.015_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ejhg.2010.4","article-title":"Therapeutic exon skipping for dysferlinopathies?","volume":"18","author":"Aartsma-Rus","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2021.04.015_bib33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/hum.2017.062","article-title":"Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy","volume":"29","author":"Potter","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.04.015_bib34","first-page":"50183","article-title":"Evaluation of muscle function of the extensor digitorum longus muscle ex\u00a0vivo and tibialis anterior muscle in\u00a0situ in mice","volume":"2013","author":"Hakim","year":"2013","journal-title":"J.\u00a0Vis. Exp."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:29:57Z","timestamp":1762421397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050121000814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":34,"alternative-id":["S2329050121000814"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.04.015","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}